XML 100 R87.htm IDEA: XBRL DOCUMENT
v3.26.1

Subsequent Events (Details) - USD ($) |  |  |  |  |  | 3 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 20, 2026 | Feb. 19, 2026 | Feb. 18, 2026 | Feb. 17, 2026 | Feb. 06, 2026 | Dec. 31, 2025 | Mar. 31, 2026 | Apr. 30, 2025 | Dec. 31, 2024
Subsequent Events |  |  |  |  |  |  |  |  |
Common stock, par value (in dollars per share) |  |  |  |  |  | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001
Settlement payable |  |  |  |  |  | $ 7,360,000 |  |  |
Number of warrants to purchase shares issued (in shares) |  |  |  |  |  | 1 | 1 |  |
Price per share (in dollars per share) |  |  |  |  |  | $ 11.5 | $ 11.5 |  |
Best efforts |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) |  |  | 8,270,000 |  |  |  |  |  |
Offering price (in dollar per share) |  |  | $ 0.29 |  |  |  |  |  |
Period of non issuance of common stock following closing date |  |  |  | 180 days |  |  |  |  |
Period of non issuance of common stock involving variable rate transaction following closing date |  |  |  | 180 days |  |  |  |  |
Placement agent fee, percent |  |  |  | 8.00% |  |  |  |  |
Placement agent fee, maximum reimbursement |  |  |  | $ 100,000 |  |  |  |  |
Net proceeds |  |  | $ 3,440,000 |  |  |  |  |  |
Pre-funded warrants |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Pre-funded warrants (in shares) |  | 1,262,000 |  |  |  |  |  |  |
Price per share (in dollars per share) |  |  | $ 0.0001 |  |  |  |  |  |
Number of shares called by each warrant |  |  | 1 |  |  |  |  |  |
Pre-funded warrants | Best efforts |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Pre-funded warrants (in shares) |  |  | 5,543,000 |  |  |  |  |  |
Number of warrants to purchase shares issued (in shares) |  |  | 5,543,000 |  |  |  |  |  |
Offering price of pre-funded warrants (in dollars per share) |  |  | $ 0.2899 |  |  |  |  |  |
Common stock purchase warrants |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Number of warrants to purchase shares issued (in shares) |  |  | 1.5 |  |  |  |  |  |
Price per share (in dollars per share) |  |  | $ 0.29 |  |  |  | 0.29 |  |
Contractual term |  |  | 5 years |  |  |  |  |  |
Common stock purchase warrants | Best efforts |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Pre-funded warrants (in shares) |  |  | 13,813,000 |  |  |  |  |  |
Number of warrants to purchase shares issued (in shares) |  |  | 20,719,500 |  |  |  |  |  |
Placement Agent Warrants |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Price per share (in dollars per share) |  |  |  | $ 0.319 |  |  | $ 0.319 |  |
Contractual term |  |  |  | 5 years |  |  |  |  |
Placement Agent Warrants | Best efforts |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Number of warrants to purchase shares issued (in shares) |  |  |  | 690,650 |  |  |  |  |
Percent of shares issued |  |  |  | 5.00% |  |  |  |  |
Percent of offering price |  |  |  | 110.00% |  |  |  |  |
Clear Street Llc |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Number of shares issued for surrender and cancellation of warrants |  |  |  |  | 4,000,000 |  |  |  |
Surrender and cancellation of warrants to purchase shares of common stock |  |  |  |  | 805,377 |  |  |  |
Settlement payable |  |  |  |  | $ 7,360,000 | $ 7,360,000 | $ 0 |  |
Loss contingency on damaged value |  |  |  |  |  | 7,500,000 |  |  |
Litigation settlement interest |  |  |  |  |  | $ 515,000 |  |  |
Innobation Bio Co. Ltd | CD47 License agreement with InnoBation |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Company issued a payment | $ 1,000,000 |  |  |  |  |  |  |  |
Subsequent Event | Best efforts |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) |  |  | 8,270,000 |  |  |  |  |  |
Offering price (in dollar per share) |  |  | $ 0.29 |  |  |  |  |  |
Period of non issuance of common stock following closing date |  |  |  | 180 days |  |  |  |  |
Period of non issuance of common stock involving variable rate transaction following closing date |  |  |  | 180 days |  |  |  |  |
Placement agent fee, percent |  |  |  | 8.00% |  |  |  |  |
Placement agent fee, maximum reimbursement |  |  |  | $ 100,000 |  |  |  |  |
Net proceeds |  |  | $ 3,460,000 | $ 3,460,000 |  |  |  |  |
Subsequent Event | Pre-funded warrants |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Price per share (in dollars per share) |  |  | $ 0.0001 |  |  |  |  |  |
Number of shares called by each warrant |  |  | 1 |  |  |  |  |  |
Subsequent Event | Pre-funded warrants | Best efforts |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Pre-funded warrants (in shares) |  |  | 5,543,000 |  |  |  |  |  |
Number of warrants to purchase shares issued (in shares) |  |  | 5,543,000 |  |  |  |  |  |
Offering price of pre-funded warrants (in dollars per share) |  |  | $ 0.2899 |  |  |  |  |  |
Subsequent Event | Common stock purchase warrants |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Price per share (in dollars per share) |  |  | $ 0.29 |  |  |  |  |  |
Number of shares called by each warrant |  |  | 1.5 |  |  |  |  |  |
Contractual term |  |  | 5 years |  |  |  |  |  |
Subsequent Event | Common stock purchase warrants | Best efforts |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Pre-funded warrants (in shares) |  |  | 13,813,000 |  |  |  |  |  |
Number of warrants to purchase shares issued (in shares) |  |  | 20,719,500 |  |  |  |  |  |
Subsequent Event | Placement Agent Warrants |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Price per share (in dollars per share) |  |  |  | $ 0.319 |  |  |  |  |
Contractual term |  |  |  | 5 years |  |  |  |  |
Subsequent Event | Placement Agent Warrants | Best efforts |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Number of warrants to purchase shares issued (in shares) |  |  |  | 690,650 |  |  |  |  |
Percent of shares issued |  |  |  | 5.00% |  |  |  |  |
Percent of offering price |  |  |  | 110.00% |  |  |  |  |
Subsequent Event | Clear Street Llc |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Number of shares issued for surrender and cancellation of warrants |  |  |  |  | 4,000,000 |  |  |  |
Common stock, par value (in dollars per share) |  |  |  |  | $ 0.0001 |  |  |  |
Surrender and cancellation of warrants to purchase shares of common stock |  |  |  |  | 805,377 |  |  |  |
Settlement payable |  |  |  |  | $ 7,360,000 |  |  |  |
Subsequent Event | Innobation Bio Co. Ltd | CD47 License agreement with InnoBation |  |  |  |  |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |
Company issued a payment | $ 1,000,000 |  |  |  |  |  |  |  |

X
- Definition Per unit amount of warrants issued. + References No definition available. + Details
Name: | limn_ClassOfWarrantOrRightIssuePricePerWarrant
Namespace Prefix: | limn_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of warrants surrendered and canceled. + References No definition available. + Details
Name: | limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled
Namespace Prefix: | limn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of warrants issued. + References No definition available. + Details
Name: | limn_ClassOfWarrantOrRightNumberOfWarrantsIssued
Namespace Prefix: | limn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of common stock payable. + References No definition available. + Details
Name: | limn_CommonStockPayable
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of maximum out-of-pocket costs and expenses incurred in connection with the Offering that will be reimbursed + References No definition available. + Details
Name: | limn_MaximumReimbursementForPlacementAgentExpenses
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of payment made for costs associated with clinical trials. + References No definition available. + Details
Name: | limn_PaymentForCostsAssociatedWithClinicalTrials
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of the public offering price for the shares of common stock and common warrants offered in the Offering representing exercise price. + References No definition available. + Details
Name: | limn_PercentOfOfferingPriceRepresentingExercisePrice
Namespace Prefix: | limn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of common stock sold in the offering, threshold percentage on the total number of outstanding shares. + References No definition available. + Details
Name: | limn_PercentOfSharesIssuedInOffering
Namespace Prefix: | limn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period during which shares will not be issued after the closing date of the offering + References No definition available. + Details
Name: | limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate
Namespace Prefix: | limn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period during which common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a variable rate transaction will not be issued after the closing date of the offering. + References No definition available. + Details
Name: | limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate
Namespace Prefix: | limn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percent of cash fee for placement agent, calculated on aggregate gross proceeds raised. + References No definition available. + Details
Name: | limn_PlacementAgentCashFeePercentage
Namespace Prefix: | limn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued for surrender and cancellation of warrants. + References No definition available. + Details
Name: | limn_SharesIssuedForSurrenderAndCancellationOfWarrants
Namespace Prefix: | limn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Interest expense (income) directly attributable to an award in settlement of litigation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_LitigationSettlementInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of damages awarded to the plaintiff in the legal matter. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=limn_ClearStreetLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=limn_InnobationBioCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |